Myelodysplastic Syndrome Clinical Trials

63 recruiting

Myelodysplastic Syndrome Trials at a Glance

255 actively recruiting trials for myelodysplastic syndrome are listed on ClinicalTrialsFinder across 6 cities in 48 countries. The largest study group is Phase 2 with 117 trials, with the heaviest enrollment activity in Houston, Boston, and Seattle. Lead sponsors running myelodysplastic syndrome studies include M.D. Anderson Cancer Center, Fred Hutchinson Cancer Center, and National Cancer Institute (NCI).

Browse myelodysplastic syndrome trials by phase

Treatments under study

About Myelodysplastic Syndrome Clinical Trials

Looking for clinical trials for Myelodysplastic Syndrome? There are currently 63 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myelodysplastic Syndrome trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myelodysplastic Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 255 trials

Recruiting
Phase 1Phase 2

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Myelodysplastic SyndromesMyelofibrosisAnemia+4 more
Disc Medicine, Inc150 enrolled24 locationsNCT05320198
Recruiting
Phase 1Phase 2

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Myelodysplastic Syndromes
National Cancer Institute (NCI)160 enrolled1 locationNCT06303193
Recruiting
Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled346 locationsNCT05564390
Recruiting
Phase 2Phase 3

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+1 more
Taiho Oncology, Inc.316 enrolled71 locationsNCT04256317
Recruiting
Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.27 enrolled22 locationsNCT04953910
Recruiting

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Acute Myeloid LeukemiaMyelodysplastic SyndromesGermline Mutation
National Cancer Institute (NCI)510 enrolled1 locationNCT07019155
Recruiting
Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.18 enrolled21 locationsNCT04953897
Recruiting
Phase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Severe Aplastic Anemia (SAA)Hypo-Plastic Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)56 enrolled1 locationNCT03520647
Recruiting
Phase 1

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center33 enrolled1 locationNCT06195891
Recruiting
Phase 1

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+6 more
National Cancer Institute (NCI)54 enrolled21 locationsNCT06484062
Recruiting
Phase 2

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Myelodysplastic Syndrome
National Cancer Institute (NCI)54 enrolled139 locationsNCT06577441
Recruiting
Not Applicable

Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis

Myelodysplastic SyndromeMyelofibrosis
Hospices Civils de Lyon13 enrolled2 locationsNCT06781099
Recruiting
Phase 1Phase 2

A Study of BGB-11417 in Participants With Myeloid Malignancies

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeiGene260 enrolled46 locationsNCT04771130
Recruiting
Phase 1Phase 2

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center52 enrolled1 locationNCT04128748
Recruiting
Phase 2

Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
University of Manitoba75 enrolled1 locationNCT06599762
Recruiting
Phase 1Phase 2

Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes

Myelodysplastic Syndromes
West Virginia University26 enrolled1 locationNCT06923488
Recruiting
Phase 2

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

Myelodysplastic Syndromes
GlaxoSmithKline80 enrolled39 locationsNCT06847867
Recruiting
Phase 1

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Myelodysplastic SyndromeRecurrent Juvenile Myelomonocytic Leukemia+3 more
Children's Oncology Group36 enrolled19 locationsNCT06247787
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic SyndromesMixed Phenotype Acute LeukemiaLeukemia, Myeloid, Acute
Orca Biosystems, Inc.80 enrolled5 locationsNCT07216443